| Prev Close | 286.31 |
| Day Low/High | 279.88 / 302.23 |
| 52 Wk Low/High | 196.78 / 404.20 |
Illumina, Inc. (ILMN)
299.89
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 146.36B |
| Market Cap | 41.90B |
| P/E Ratio | 61.31 |
| Div & Yield | N.A. (N.A) |
Latest News
6 Testing, Diagnostics and Medical Devices Stocks You Should Know About
Look for weaknesses in companies like these that can provide solutions to today's pressing issues.
4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech
These ARK Funds family funds are focused on new opportunities and investment themes.
What Are the Factors That Will Drive Fourth Quarter Moves in the Markets?
When things are going well it is always difficult to see an inflection point.
How I Knew to Bet Against Tesla, Netflix and Other Stocks
Hint: I did my homework and acted when I felt I had the advantage over other market players.
Here's 2 Very Lucrative Trades From My New Trading Venture
When stock fundamentals and stock valuations diverge, profit opportunities are created.
Illumina, One of My Short Stock Candidates, Shows Mediocre Growth
ILMN shares were down about 15% in Friday trading after they pre-announced a revenue miss for its second quarter.
Coming Up Short? Here Are Some Stocks to Consider
To effectively generate profits, a trader must pick several companies in a sector and short the whole bunch.
These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies
Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'
5 Attractive Ways to Invest in Oncology
Experts offer their top stock ideas in oncology detection and treatment.
Illumina Could Rally to Break Its Downtrend
Here's how we would play ILMN stock right now.
Jim Cramer: Know Which Way the Wind Blows Before You Pick Stocks
PepsiCo, GE and just like the weather, the stock market is subject to change.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Jim Cramer: Valuations Now Have No Relation to Common Sense
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
Illumina's Pullback Looks Like a Buying Opportunity for Further Gain
Look for gains in Illumina shares to $300 and then perhaps around $340.
Consider Going Long Illumina
Illumina could offer a profitable sequence.
Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back
The crash of oil will only accelerate the move.
Jim Cramer: Follow the Bouncing Equities
Markets start day with a bungee jump.
Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections
Watch for these upstart names to topple some big-caps going forward.
Jim Cramer: The 3 Best Sectors That Lifted the Stock Market
It's hard to understand the magnitude of the change.
Cramer: Lessons From the Market and ICR
You can make a case to buy any of the stocks of the companies at ICR.
Six Off the Beaten Path Healthcare Stock Gems
These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.
Illumina Lights the Way for Biotechs
Today's breakout move in the stock is a highlight of the surging sector.
Illumina Lights the Way for Biotechs
Today's breakout move in the stock is a highlight of the surging sector.
Trader's Daily Notebook: Anemic Trading Would Be an Improvement
Slow markets like this demand a less-is-more approach.
Cramer: There Are Powerful Themes in Several Bull Markets
It's a wonder to me how split this market really is.
